Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Erkki Ruoslahti
AddedMar 31, 2024
UpdatedMay 31, 2026
Erkki Ruoslahti

Erkki Ruoslahti

Co-Founder, Lisata Therapeutics

Crunchbase

Erkki Ruoslahti's Career

Lisata Therapeutics
Lisata Therapeutics

Basking Ridge, NJ, US

Co-Founder
AivoCode
AivoCode

San Diego, CA, US

Board Member· Board
FibRx Derm
FibRx Derm

Berkeley, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Erkki Ruoslahti's Career

Lisata Therapeutics
Lisata Therapeutics
Public$165.6M5001980Basking Ridge, NJ, US
Co-Founder

Leadership at Lisata Therapeutics

Cynthia SchwalmCynthia SchwalmBoard Member
Anastasia MannAnastasia MannBoard Member
Steven KloskSteven KloskBoard Member
David J. MazzoDavid J. MazzoCEO
Catherine VaczyCatherine VaczyCo-Founder
Mohammad AzabMohammad AzabBoard Member

Similar to Lisata Therapeutics

Lusaris TherapeuticsLusaris TherapeuticsBoston, MA, USTherapeuticsest. 2021Lusaris TherapeuticsBoston, MA, US · est. 2021

Lusaris: A biotech firm pioneering advanced therapeutics for severe neuropsychiatric disorders.

Series A · $60M6
Thetis PharmaceuticalsThetis PharmaceuticalsRidgefield, CT, USDrug Developmentest. 2011Thetis PharmaceuticalsRidgefield, CT, US · est. 2011

Thetis Pharmaceuticals: Specializing in cardio-metabolic, cancer, and autoimmune disease treatments.

Series A · $22.9M30
Lyst TherapeuticsLyst TherapeuticsColumbus, OH, USHealth Researchest. 2015Lyst TherapeuticsColumbus, OH, US · est. 2015

Lyst Therapeutics: Pioneering health research to inhibit vascular graft stenosis at Nationwide Children's Institute.

Seed · $400k6
Lysosomal TherapeuticsLysosomal TherapeuticsCambridge, MA, USDrug Developmentest. 2011Lysosomal TherapeuticsCambridge, MA, US · est. 2011

US-based Lysosomal Therapeutics Inc innovates in neurodegeneration research, developing treatments for severe neurological diseases.

Series A · $24.8M5
AivoCode
AivoCode
Seed$5.6M82016San Diego, CA, US
Board Member· Board

Leadership at AivoCode

Aman MannAman MannCo-Founder
Sazid HussainSazid HussainCo-Founder

Similar to AivoCode

NeuroX1NeuroX1Austin, TX, USDrug Discoveryest. 2021NeuroX1Austin, TX, US · est. 2021

NeuroX1: A computational startup designing novel compounds for neurodegenerative diseases using our proprietary platform.

Seed · $1.8M6
Neuro42Neuro42Oakland, CA, USMedical Devicesest. 2020Neuro42Oakland, CA, US · est. 2020

neuro42: Innovating advanced MRI tech for diagnosing and treating neurological conditions.

Series B · $12.8M26
NeuralyNeuralyGermantown, MD, USTherapeuticsest. 2016NeuralyGermantown, MD, US · est. 2016

Neuraly, Inc.: A biotech firm developing neuro-protective therapies for neurological disorders.

Series A · $36M125
ConvalesceConvalesceSan Francisco, CA, USStem Cell Therapyest. 2018ConvalesceSan Francisco, CA, US · est. 2018

Convalesce: Pioneering stem cell therapies for neurodegenerative conditions using advanced biomaterials.

Angel · $250k3
FibRx Derm
FibRx Derm
Seed$1.8M62018Berkeley, CA, US
Co-Founder

Leadership at FibRx Derm

Mark De SouzaMark De SouzaCo-Founder
James FordyceJames FordyceCo-Founder

Similar to FibRx Derm

DermBiontDermBiontBoston, MA, USTherapeuticsest. 2017DermBiontBoston, MA, US · est. 2017

DermBiont: A leading precision dermatology firm, developing targeted therapeutics for skin health.

Series B · $108.5M47
Rnaderm TherapeuticsRnaderm TherapeuticsBerkeley, CA, USBiotechest. 2018Rnaderm TherapeuticsBerkeley, CA, US · est. 2018

Berkeley-based biotech company, RNADerm Therapeutics.

Seed · $750k5
ElucidermElucidermSan Diego, CA, USWound Healingest. 2018ElucidermSan Diego, CA, US · est. 2018

Eluciderm, a San Diego-based medical firm, innovates scarless wound healing products since 2018.

Seed · $2M5
SironRX TherapeuticsSironRX TherapeuticsCleveland, OH, USRegenerative Therapiesest. 2010SironRX TherapeuticsCleveland, OH, US · est. 2010

SironRX Therapeutics: Innovating regenerative therapies for wound repair and scar prevention in the US.

Series A · $3.9M6

Erkki Ruoslahti's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Erkki Ruoslahti

Geoff BrookeGeoff BrookeCo-Founder · GBS Venture PartnersPaul L. KornblithPaul L. KornblithFounder · HelomicsDavid PerryDavid PerryCo-Founder · NexpriseTerry LiermanTerry LiermanBoard Member · WelldocAdam RensloAdam RensloCo-Founder · Elgia TherapeuticsMike RossMike RossBoard Member · Deciphera Pharmaceuticals